Last reviewed: June 22, 2026
Last updated: June 22, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Urinary tract infections (UTIs) are not listed as a common side effect of Ozempic in FDA labeling, yet patients and healthcare providers have reported this concern during GLP-1 therapy. Research into the mechanisms behind this association reveals multiple physiological pathways that may increase UTI risk in certain individuals.
How GLP-1 Medications May Increase Urinary Tract Infection Risk
GLP-1 receptor agonists like semaglutide slow gastric emptying and reduce appetite, which can lead to decreased fluid intake when patients are not intentionally hydrating. Lower urine volume concentrates bacterial populations in the bladder, creating an environment where infection becomes more likely. Additionally, rapid weight loss associated with GLP-1 therapy triggers metabolic shifts that may alter urine pH and glucose levels, both of which influence bladder bacterial colonization.
Some individuals experience nausea during initial semaglutide dosing, which further discourages drinking water and other fluids. Dehydration remains one of the most modifiable risk factors for UTI development, making hydration awareness essential for GLP-1 patients. PlexusDx recommends patients maintain a structured daily fluid intake—typically 2-3 liters—even when appetite signals suggest otherwise.
Genetic Factors That Predispose Some Patients to UTIs on Semaglutide
Not all individuals on GLP-1 therapy experience increased UTI risk, suggesting that genetic variation plays a protective or permissive role. The PlexusDx Precision Peptide Genetic Test maps 14 metabolic pathways and identifies variants in genes controlling glucose reabsorption, immune response, and renal filtration. Specific genetic polymorphisms—including markers in genes affecting urinary glucose handling—can predict which patients are more vulnerable to infection during weight loss treatment.
Patients carrying certain variants in genes related to glucose-dependent renal reabsorption may experience glucosuria (glucose in urine) at higher rates when on semaglutide, providing additional substrate for bacterial growth. The Precision Peptide Genetic Test delivers actionable insights about these pathways so PlexusDx can tailor hydration counseling and monitoring protocols to individual genetic risk profiles.
Practical Prevention Strategies for GLP-1 Users
Intentional hydration is the first-line defense against UTI during semaglutide therapy. Set hourly water intake goals (8 ounces per hour while awake) and use reminders on your phone, since GLP-1 appetite suppression may mask normal thirst signals. Urinate regularly every 2–3 hours and empty your bladder completely each time; incomplete emptying leaves residual urine that allows bacterial multiplication.
Dietary adjustments amplify hydration benefits: increase intake of cranberry juice or cranberry supplements, which contain compounds that may prevent bacterial adhesion to bladder cells. Avoid bladder irritants—including caffeine, artificial sweeteners, and spicy foods—during the first weeks of semaglutide treatment when nausea peaks. Maintain good personal hygiene, particularly after bowel movements, and discuss any recurrent UTI history with your prescribing clinician before starting GLP-1 therapy.
When to Seek Medical Care and How PlexusDx Monitors Your Health
Contact your healthcare provider immediately if you experience burning with urination, urgency, frequency, lower abdominal or pelvic pain, fever, or cloudy urine while taking semaglutide. Early treatment with antibiotics can prevent progression to pyelonephritis (kidney infection) and serious complications. PlexusDx recommends patients track urinary symptoms weekly via our patient portal and report changes at each check-in appointment.
PlexusDx compounded semaglutide (starting at $149/month) is supplied by licensed 503A compounding pharmacies and includes access to clinical coaching that covers hydration protocols and symptom recognition. If UTI becomes recurrent, your PlexusDx provider may recommend the Precision Peptide Genetic Test ($99 add-on) to identify underlying genetic predispositions and adjust your treatment plan accordingly. This personalized approach ensures your weight loss therapy supports overall health rather than introducing new complications.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Is urinary tract infection a known side effect of Ozempic listed by the FDA?
UTI is not listed as a common adverse event in Ozempic's FDA labeling, but patient reports and clinical observations suggest GLP-1 medications may increase risk through dehydration and metabolic changes. Your healthcare provider should monitor symptoms and adjust hydration guidance based on your individual experience.
What clinical evidence connects GLP-1 medications to urinary tract infections?
While large randomized trials do not specifically measure UTI incidence, mechanistic studies show GLP-1 agonists reduce fluid intake, concentrate urine, and alter glucose handling—all factors that increase UTI risk. Real-world patient reports align with these physiological pathways, prompting increased clinical awareness.
How much does compounded semaglutide cost at PlexusDx?
PlexusDx compounded semaglutide injection starts at $149 per month across all dosing levels. Your dose may need to go up. Your price won't. PlexusDx serves all 50 states without insurance requirements and accepts HSA/FSA funds.
Can the PlexusDx Precision Peptide Genetic Test predict my UTI risk on GLP-1 therapy?
The Precision Peptide Genetic Test ($99 add-on after your first month of treatment) identifies genetic variants affecting glucose reabsorption, immune function, and renal pathways—all of which influence UTI susceptibility during semaglutide use. These insights help PlexusDx clinicians personalize hydration protocols and monitoring intensity.
Should I stop taking semaglutide if I develop a UTI?
Do not stop semaglutide without speaking to your healthcare provider. A single UTI is treatable with antibiotics and does not typically require discontinuation. However, recurrent infections may signal the need to reassess hydration strategies, adjust your treatment plan, or pursue genetic testing to identify underlying risk factors.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
How to Come Off Wegovy and Not Gain Weight
Is Zepbound Injected Subcutaneously? A Comprehensive Guide to Understanding Zepbound Injections